Discovery could make reversible gene therapy a reality
A new study has presented an innovative electromagnetic field (EMF)-responsive gene switch that enables fully reversible, safe, and precise control over gene expression.
“Gene switches” hold significant potential for understanding gene expression and for therapeutic applications, particularly for the non-invasive treatment or management of genetic disorders.
In recent years, researchers have developed several gene switches that enable the remote control of gene expression in living organisms using stimuli such as drugs, light, heat, ultrasound, and electrical signals. However, current versions are limited in offering precise control over the timing and duration of gene expression.
Additionally, drug-based gene switches can have undesirable adverse effects, while some stimuli such as light can make penetrating deeper tissues challenging.
The research was led by Professor Jongpil Kim and dDoctoral student Yerim Hwang from the Institute for Stem Cells and Regenerative Medicine, at Dongguk University, Republic of Korea.
“In previous studies, extremely low frequency EMF fields have been shown to modulate expression of specific genes involved in stress response, epigenetic remodelling, and cellular signalling pathways. Moreover, EMF is non-invasive, fully-reversible, and can precisely penetrate target tissues or areas of the body, making them highly attractive for remote control of gene switches,” explained Professor Kim. “In this study, we utilised the promoter of the Lgr4 gene to create a robust EMF-inducible gene switch, and demonstrated its applications in Alzheimer’s disease (AD) modelling and reversing ageing markers in mice.”
Simpler, real-time treatment
To identify EMF-responsive genes, the researchers performed single-cell RNA sequencing (scRNA-seq) on mouse brain tissue following exposure to an EMF of 2.0 millitesla at 60 hertz. They found exclusive upregulation of Lgr4 expression. Through a series of validation experiments, the team found that the promoter of Lgr4 was well suited for constructing an EMF-inducible (Ei) gene switch, exhibiting precise activation with no detectable adverse effects during the study.
To evaluate the system in living animals, the researchers linked the Ei element to a reporter that produces green fluorescent protein (GFP), allowing gene activity to be visualised. They then generated transgenic mice carrying this reporter. Following EMF exposure, the mice showed strong GFP expression throughout the body, while targeted EMF exposure produced localised gene expression in specific organs. When EMF stimulation was discontinued, gene expression returned to baseline within 24 hours, demonstrating that the Ei gene switch is highly tunable, reversible, and capable of precise remote control of gene expression.
Using a genome-wide CRISPR-Cas9 knockout screen, the researchers identified cytochrome b5 type B (Cyb5b), a membrane-associated protein, as the biological sensor for EMF. Further tests revealed that due to EMF-exposure, Cyb5b produces rhythmic, oscillating calcium influx oscillations in cells, functioning as a specific code for activating the target gene.
The researchers also established an AD mouse model that decouples brain ageing from amyloid β plague deposition. In addition, cyclic EMF exposure was used to achieve partial cellular reprogramming in aged and progeroid mice, improving several ageing-associated markers without detectable adverse effects. The team also restored serotonin levels and reduced depression-like behaviours in mice by controlling expression of the Tph2 gene.
“This technology could move gene therapy away from a single, irreversible dose and toward simpler, real-time treatments administered by physicians or even wearable devices,” shared Hwang.
